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ABSTRACT
Positron emission tomography (PET) has become one of the major tools for the in vivo localisation of positron-
emitting tracers and now is performed routinely using 
18F-fluorodeoxyglucose (FDG) to answer important clinical
questions including those in cardiology, neurology, psychiatry, and oncology. The latter application contributed largely
to the wide acceptance of this imaging modality and its use in clinical diagnosis, staging, restaging, and assessment of
tumour response to treatment. Dual-modality PET/CT systems have been operational for almost a decade since their
inception. The complementarity between anatomic (CT) and functional or metabolic (PET) information provided in a
“one-stop shop” has been the driving force of this technology. Although combined anato-metabolic imaging is an
obvious
 choice, the way to perform imaging is still an open issue. The tracers or combinations of tracers to be
  used, how
the imaging should be done, when contrast-enhanced CT should be performed, what are the
  optimal acquisition and
processing protocols, are all unanswered questions. Moreover, each data acquisition–processing combination may
  need
to be independently optimised and validated. This paper briefly reviews the basic principles of dual-modality imaging
and addresses some of the practical issues involved in optimising PET/CT scanning protocols in a clinical environment.
© 2007 Biomedical Imaging and Intervention Journal. All rights reserved.
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INTRODUCTION 
Diagnosis, staging, treatment, prognosis and follow-
up  are  the  principal  elements  in  the  management  of
cancer, and nuclear medicine plays an important role in
all these elements. Among all diagnostic and therapeutic
procedures, nuclear medicine is unique in that it is based
on molecular and pathophysiological mechanisms, and
employs radioactively labelled biological molecules as
tracers to study the pathophysiology of the tumour in
vivo to direct treatment and assess response to therapy
[1]. The specific role of PET imaging in the expansion of
our understanding of the pathophysiological mechanisms
of cancer and in the clinical management of patients is
steadily  progressing.  PET,  an  imaging  modality  with
sensitivity in the picomolar range, allows in vivo non-
invasive 3D imaging of regional metabolism and many
other  physiological  mechanisms.  Since  functional
disturbances occur often earlier than structural once, a
faster and more sensitive detection is possible.
Whereas  the  advent  of  dedicated  dual-modality
imaging systems designed specifically for clinical use is
relatively recent, the potential advantages of combining
anatomical and functional imaging has been recognised
for several decades by pioneering radiological scientists
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and physicians [2]. Combining anatomical and functional
or metabolic information into a fused image has been
pursued for a long time. Early attempts were made by
software  fusion  of  PET/SPECT  and  x-ray  CT/MR
images [3]. However, these efforts often come across
significant limitations, particularly in cases with non-
explicit differential diagnosis or in parts of the body
other than the brain. The coregistration of brain images is
relatively straightforward owing to its rigid structure,
whereas especially in the abdomen or thorax an exact
repositioning of the patient on two different scanners
(usually physically located in two different departments
involving different operators) is tricky and makes the
precise  alignment  of  images  from  two  modalities
doubtful  [4].  However,  in  any  case  a  hardware
combination in a single gantry of multimodal imaging
devices ensures a much better alignment of the images
and gives much higher confidence to the clinicians [5]. A
hardware  combination  of  imaging  modalities  (e.g.
PET/CT) not only provides optimally aligned images,
but  also  simplifies  the  logistics  of  scheduling  and
organising  patients’  scanning  given  that  PET/CT
presents  the  opportunity  for  a  ‘one  stop-shopping’
approach [6].
Although combined anato-molecular imaging is an
obvious
 choice, the design of specific clinical protocols
and flexible workflow utilities is still under development
and  open  to  debate.  The  tracers  or  combinations  of
tracers to be
 used, when and how the imaging should be
done, the selection of optimal acquisition, processing and
display  protocols,  and  the  method  of  accurately
performing  quantitative  analysis  of  data  are  still
undetermined.  This  review  documents  technological
advancement  of  the  field  of  PET/CT  imaging  where
special  emphasis  is  put  on  optimised  clinical  data
acquisition protocols and strategies to reduce artefacts
and interpretative pitfalls.
PRINCIPLES OF PET/CT: THEORY AND PRACTICE
The first combined PET/CT prototype allowing the
acquisition  of  functional  and  anatomical  images  in  a
single session on the same scanner bed was developed in
the late 1990s by investigators from the University of
Pittsburgh [7]. This hybrid unit consists of two separate
devices, namely a PET and a CT scanner, linked by one
common bed and workstation console where data from
both  modalities  are  acquired  sequentially  rather  than
simultaneously as planned during the earlier conceptual
design of the machine [8]. Both the CT components and
the PET detectors were mounted on opposite sides of the
rotating stage of the CT system, and imaged a patient
with  a  common  patient  table  translated  between  the
centres of the two tomographs which are offset axially by
60 cm. The PET/CT system has a specially designed
patient  table  that  is  designed  to  minimize  deflection
when it is extended into the patient port. The PET/CT
prototype was operational at the University of Pittsburgh
from May 1998 to August 2001, during which over 300
cancer patients were scanned [9]. The success of these
initial  studies  prompted  significant  interest  from  the
major medical imaging equipment manufacturers who
now all have introduced commercial PET/CT scanners
for clinical use.
Commercial PET/CT systems are usually configured
by  designing  a  gantry  that  mounts  a  stationary  PET
detector ring in tandem with a platform that rotates the
CT imaging chain around the patient using a mechanical
configuration similar  to  that  used  in  a  conventional
diagnostic CT scanner. The CT study typically is used
for both localisation of the FDG uptake as well as for
attenuation correction of the PET data set. Besides, the
use of CT in comparison to radionuclide transmission
sources  for  producing  the  attenuation  data  increases
patient  throughput  by  approximately  30%  [10].
However, CT also increases patient dose and despite the
significant progress achieved in CT-based attenuation
correction  (CT-AC)  during  the  last  decade,  some
problematic issues still remain open research questions
and  are  being  investigated  by  many  active  research
groups [11, 12].
The  major  area  of  clinical  use  of  PET/CT  is  in
oncology,  where  the  most  commonly  used
radiopharmaceutical  is 
18F-fluorodeoxyglucose (FDG).
FDG-PET has already had a huge valuable outcome on
cancer treatment and its use in clinical oncology practice
continues  to  develop  [13,  14].  The  advantages  of
combining  morphological  and  functional  imaging
(compared  to  PET  or  CT  alone)  have  been  clearly
demonstrated  by  numerous  publications  for  a  wide
variety of applications [9, 15-17]. There is an abundant
literature reporting patient studies where the combined
PET/CT images provided additional information, thus
impacting the characterisation of abnormal FDG uptake
and influencing patient management.
The recent progress in the development of tracers
targeted to other aspects of tumour biology, including
cell  growth,  cell  death,  oncogene  expression,  drug
delivery, and tumour hypoxia will significantly enhance
the  capability  of  clinical  scientists  to  differentiate
tumours and are likely to be used to guide treatment
decisions. The contribution of PET to understanding the
clinical  biology  of  cancer  and  to  guiding  targeted,
individualised therapy will continue to grow with these
new developments [18, 19]. Central to this expanding
role in oncology will be the ability to make quantitative
interpretations of the PET imaging data [1].
STANDARD PET/CT SCANNING PROTOCOLS
Figure 1 shows the essential steps that comprise a
typical  PET/CT  scan,  demonstrating  the  degree  of
integration available in a modern dual-modality imaging
system  [20].  (i)  The  patient  is  prepared  for  imaging
which  commonly  includes  administration  both  with
contrast media [21] and with the radiopharmaceutical,
typically 370 to 555 MBq (10 to 15 mCi) of 
18F-FDG in
adults. (ii) The patient then is asked to remove all metal
2H Zaidi. Biomed Imaging Interv J 2007; 3(2):e36
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Figure 1 Principles of a typical PET/CT data acquisition protocol showing the main hardware components of a
hybrid imaging system and the major steps involved for generating the attenuation map required for CT-
based attenuation correction.
CT CT-AC non-AC
Figure 2 Oral contrast-enhanced related artefact in clinical PET/CT imaging. The region concentrating oral
contrast shown on CT (left, arrows) led to areas of apparently increased glucose metabolism on CT-
based attenuation corrected PET (centre, arrows). On fused PET/CT images, this area of apparently
increased  glucose  metabolism  correlated  with  high-density  oral  contrast  on  CT  (not  shown).
Reconstructed PET images without attenuation correction demonstrated absence of lesions (right),
demasking areas of apparently increased glucose metabolism as artefact. Courtesy of Prof. H. Abdel-
Dayem.
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objects that could introduce artefacts in the CT scan and
then  is  positioned  on  the  patient  table  of  the
dual/modality  imaging  system.  (iii)  The  patient  then
undergoes an “overview” or “scout” scan during which
x-ray projection data are obtained from the patient to
identify the axial extent of the CT and PET study. (iv)
The patient undergoes a CT acquisition. (v) The patient
then  undergoes  the  nuclear  medicine  study
approximately 1 hour after FDG administration. (vi) The
CT and PET data then are reconstructed and registered,
with the CT data used for attenuation correction of the
reconstructed  PET  tomograms.  (vii)  The  images  are
reviewed by a physician who can view the CT scan, the
PET  images,  and  the  fused  x-ray/radionuclide  data,
followed by preparation of the associated clinical report.
In practice, however, running a PET/CT scanner in a
clinical  environment  to  the  uppermost  diagnostic
standards  is  not  straightforward.  Translating  the
experience  and  know-how  gained  in  radiology  to  a
nuclear medicine department and vice versa is not that
easy owing to the controversies surrounding PET/CT and
the existing territorial and protective practices in health
care  facilities.  Careful  patient  preparation  and
positioning are key elements of the long chain of data
acquisition  and  processing  protocols  and  require
extensive training of technologists operating the scanner
to minimize artifacts and reduce interpretative pitfalls.
As mentioned above, notwithstanding the success
and widespread clinical adoption of PET/CT, there are
several  challenges  that  face  the  use  of  dual-modality
imaging, and that may represent inherent limitations in
this technique. In addition to a much higher absorbed
dose  to  the  patient,  there  are  many  physical  and
physiological  factors  that  hamper  the  accurate
registration of both imaging modalities and the accurate
quantitative  analysis  of  PET  data  following  CT-AC
including the inherent difference between CT and PET
image matrix size and resolution, polychromaticity of x-
ray  photons  (30-140  keV) requiring transformation to
monoenergetic  511  keV  photons  [22], misregistration
between CT and PET images resulting for instance from
respiratory motion [23-26], truncation artefacts owing to
discrepancy  between  fields  of  view  in  a  combined
PET/CT  scanner  [27-29],  the  presence  of  oral  and
intravenous contrast medium [21, 30-38], artefacts due to
metallic implants [39-46], beam hardening [47, 48], x-
ray scatter in CT images for future generation cone-beam
geometries  [49-51],  and  other  CT  artefacts  from  any
source.  As  an  example,  figure  2  illustrates  typical
artefacts  resulting  from  the  presence  of  oral  contrast
medium  during  PET  scanning  when  using  CT-based
attenuation correction in PET.
In particular, metal artefacts are a major problem in
CT. They are due to the presence of strongly attenuating
objects in the field-of-view. The presence of metallic
dental implants can also introduce artefacts into brain
images,  not  only  when  CT  is  used  to  determine  the
attenuation map in PET/CT, but also when a standard
positron source is employed for attenuation correction
[44].  A  limited  number  of  studies  reported  in  the
literature  detailed  comparative  assessment  studies
between CT-AC and radionuclide scanning-based AC
including 
68Ga vs CT-AC and 
137Cs vs. CT-AC [12]. The
most important causes of metal artefacts are: noise, beam
hardening,  the  non-linear  partial  volume  effect,  and
scatter. In order to develop new algorithms for reduction
of metal artefacts, one usually hypothesize that artefacts
are due to deviations of the acquisition model assumed
by the reconstruction from the true acquisition process.
Consequently, improving the acquisition model should
reduce artefacts.
Qualitative visual assessment remains the principal
method followed in the interpretation of routine clinical
PET studies. Qualitative interpretation of clinical FDG-
PET  scans  is  usually  based  on  the  identification  of
regional glycolysis through a differential assessment of
the contrast between sites of tracer uptake resulting from
a normal physiological process or a pathological state
compared  to  the  surrounding  background.  However,
visual interpretation intrinsically bears many important
weaknesses including the need to define a threshold for
judgment  of  the  existence  and  degree  of  radiotracer
concentration among other physical and physiological
factors,  issues  related  to  inter-  and  intra-observer
reliability for qualitative assessment in clinical trials,
…etc. Therefore, despite its simplicity, critical role and
wide  adoption  in  the  daily  clinical  practice,  visual
interpretation has many fundamental shortcomings which
limit its role in research studies where more emphasis is
put on quantitative measures that allow more objective
and reliable assessment.
Currently,  the  standardised  uptake  value  (SUV)
continues to be the most widely used uptake index in
clinical PET studies. This semi-quantitative parameter is
defined as the tissue concentration of tracer within a
lesion divided by tissue density, as measured by PET,
divided by the injected dose normalised to patient weight
multiplied by a decay factor [52]. In practice, the SUV is
calculated by dividing the activity concentration
  in the
region  of  interest  (ROI)  drawn  around  the  lesion
(MBq/mL) by
  the injected dose (MBq) divided by the
body weight (g):
factor decay
g weight Body
MBq dose Injected
cc g density Tissue
cc MBq ion concentrat activity Mean
SUV
1
) (
) (
) / (
) / (
× =
Since the weight is not always a good measure of
initial tracer distribution volume, several investigators
suggested variants on the SUV to account for this effect
particularly for obese patients. This includes SUV using
lean-body mass (lean) [53] or body surface area (BSA)
[54] in place of patient weight in the equation above,
yielding SUVlean and SUVBSA, respectively, to reduce the
variation  of  SUV  associated  to  patient’s  body
composition and habitus. For research studies, simplified
and more rigorous tracer kinetic analysis techniques are
usually adopted [55].
In addition to the factors discussed above, it has
been reported in many studies that variations in the time
interval  between  tracer  injection  and  PET  scanning
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(uptake period) considerably influence SUV estimation
[55, 56]. It should be emphasised that in many of these
studies,  dual-time  point
  PET  improved  both  the
sensitivity
  and the specificity of PET for a variety of
malignancies,  including  breast  cancer  [57-59],  lung
nodules [60], head and neck cancer [61] and gallbladder
carcinoma [62].  In  theory,  this  is  the  result  of  two
factors: firstly the sustained augmented FDG uptake in
malignant  lesions  allows  to  discriminate  them  with
higher  specificity,  and  secondly,  enhanced  lesion-to-
background
  contrast  leads  to  improved  lesion
detectability  (Fig.  3).  The  later  is  the  result  of  a
combination of FDG washout from neighbouring normal
tissues and enhanced FDG uptake in the lesion. This is
remarkable given that there is always a trade-off between
sensitivity  and  specificity  for  the  majority  of  other
diagnostic imaging investigations, frequently suggesting
that improvement in performance of one parameter can
be achieved only at the detriment of the second and vice
versa [55].
OPTIMISATION OF PET/CT SCANNING PROTOCOLS
Despite the fact that PET/CT became the de facto
standard  for  clinical  PET  imaging,  there  are  several
challenges  that  face  its  use  and  that  may  represent
inherent limitations in this technique. All commercially
available  PET/CT  systems  record  the  emission  and
transmission data using different detectors instead of a
single detector. Moreover, the x-ray and PET imaging
chains  are  separated  by  a  non-negligible  distance,  to
facilitate mechanical clearance and to avoid blinding and
damaging the PET detectors and contaminating the x-ray
CT data by scatter radiation emanating from the emission
PET scan. One probable trouble arises when the patient
moves  either  voluntarily  or  involuntarily  between  or
during the CT and PET data acquisitions. This might
take  place,  for  instance,  if  the  patient  changes  his
position while lying on the patient bed. Patient motion
might  also  occur  due  to  respiration,  cardiac  motion,
peristalsis, and bladder filling, all of which can lead to
motion blurring or misregistration errors between PET
and CT data [17]. Diagnostic quality CT data are usually
acquired using a breath-hold protocol, whereas PET data
are  acquired  over  several  minutes  with  the  patient
breathing  softly.  Differences  between  PET  and  CT
breathing protocols might lead to misalignment artefacts
owing to anatomical dislocations of the diaphragm and
chest wall during a PET/CT scan. A slight displacement
of the diaphragm’s position on the CT scan can cause a
substantial  bias  in  the  estimation  of  the  tracer
concentration in the reconstructed PET data when the
former  is  used  for  attenuation  correction  [63].  The
outcome of an inconsistency in diaphragmatic location
Figure 3 Comparison of early and delayed FDG-PET images from a lung cancer patient. transaxial images (A)
and coronal images (B). Arrow points to lesion. Malignant focus became more apparent in later images
and SUV increased from 3.77 to 5.55. Reprinted with permission from [56].
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(A) (B)
(C) (D)
Figure  4 Illustration of a respiratory motion related artefact on PET images reconstructed with CT-based
attenuation correction. (A) coronal 
18F-FDG PET, (B) Coronal CT, and (C) sagittal 
18F-FDG PET, and
(D) sagittal CT. A region of decreased metabolic activity is demonstrated in the diaphragmatic region
(horizontal arrow), representing a “cold artefact”.
Figure 5 Illustration of a cardiac motion related artefact on PET images reconstructed with CT-based attenuation
correction showing the anatomical CT images (left), PET image (centre), and the fused PET/CT image
(right).
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between PET and CT is frequently the appearance of the
so-called “cold” artefact at the lung base (Fig. 4). Many
studies reported significant misalignment between the
CT and the PET data. For example, in a study of 300
clinical  PET/CT  studies  with  proven  liver  lesions;
approximately 2% appeared to have the lesion localised
in the lung [64] whereas the misalignment between PET
and CT data was greater than 2 cm in 34 of 100 patient
studies due to respiratory motion [65]. Cardiac motion
can also be a source of misregistration between the CT
and PET images (Fig. 5).
Caution  is  therefore  commended  when  reading
PET/CT  scans  of  patients  suffering  from  disease  in
periphery of the lung where noticeable tracer uptake can
be the result of respiratory motion rather than disease.
Modern PET/CT scanners are equipped with helical CT
technology  allowing  to  acquire  high  resolution
anatomical  images  within  a  few  seconds  following
patient positioning and definition of the axial field of
view on the topogram. It is therefore obvious that PET is
the limiting factor when it comes to scanning speed on
combined PET/CT. Whenever faster scanning times are
sought,  PET  is  the  imaging  modality  requiring
improvement through the development of novel detector
technologies, faster scintillation crystals and electronic
boards, new geometries offering higher sensitivity and
many  other  means  that  are  being  explored.  One
possibility  would  be  to  substitute  conventional  PET
detector blocks with LSO panel detectors [66] covering a
larger axial field of view with the aim of achieving faster
scan times than are achievable with current systems. In
any case, faster scan times improve both patient comfort
and reduce the time during which patient motion can
occur. Likewise, faster scan times can increase patient
throughput  and  thereby  boost  system  utilisation  and
improve cost-effectiveness.
The  progress  in  CT-AC  methodology  has  been
immense in the last few years, the main opportunities
arising from the development of both optimised scanning
protocols and innovative and faster image processing
algorithms. This has permitted the implementation of
much  more  ambitious  algorithms  that  tackle  the
challenges  of  whole-body  imaging  using  PET.  Some
solutions were recently proposed and used successfully
in clinical and research settings. This includes optimised
contrast-enhanced  CT  protocols  [38,  67],  respiratory
motion [65, 68, 69], metal artefacts reduction [70-89],
truncation artefacts correction [27-29], beam hardening
[47,  48]  and  x-ray  scatter  [49-51].  These  hot  topics
undoubtedly  still  require  further  research  and
development efforts.
CHALLENGES AND FUTURE DIRECTIONS
One decade elapsed since the introduction of dual-
modality  PET/CT  imaging  in  clinical  routine.  The
supporters  of  this  imaging  modality  claim  that  the
barriers  for  wider  adoption  of  this  technology  were
driven by bureaucratic and protective motivations rather
by scientific reasons [90]. Still there are many technical
issues  that  need  to  be  solved  through  research  [91].
Despite much worthwhile research performed during the
last few years, artefacts induced by respiratory motion
remain among the most difficult problems to solve [92,
93]. Another limitation of current PET/CT technology is
that sequential rather than simultaneous data acquisition
is performed [11].
Sequential scanning renders an accurate temporal
correlation of non-repeatable functional in vivo processes
impractical,  which  is  a  major  restriction  of  current
generation PET/CT scanners [1]. Moreover, CT has low
soft tissue contrast and delivers pretty high absorbed
radiation doses, which can result in noticeable biological
effects, a rather serious issue particularly in paediatric
studies. This might also change the animal model being
studied in preclinical research using molecular imaging
techniques  ending  up  with  unreliable  results.  More
importantly, owing to its low sensitivity, perfusion is the
only in vivo functional information provided by CT in
contrast  enhanced  studies.  This  is  in  contrast  to
capabilities and the wealth of information offered by
MRI (in addition to higher soft tissue contrast) through
fMRI and MR spectroscopy to enhance the diagnostic
performance and quantitative capabilities of PET [3, 94].
Whether PET/MR will succeed to replace PET/CT as the
multimodality molecular imaging platform of choice in
the future is still an open and important question that will
retain  the  attention  of  active  researchers  in  the  field
during the next decade [95, 96].
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